Risk of hepatitis B reactivation in HBsAg−/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: A meta‐analysis

Risk of hepatitis B reactivation in HBsAg−/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: A meta‐analysis

Abstract Background The risk of hepatitis B virus (HBV) reactivation after biologic and targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) therapy in patients with rheumatoid arthritis (RA) combined with HBsAg–/HBcAb+ is still inconsistent. Methods We conducted a systematic review...

Full description

Bibliographic Details
Main Authors: Xuezhi Hong, Yanhua Xiao, Liyan Xu, Lei Liu, Hailu Mo, Hanyou Mo
Format: Article
Language:English
Published: Wiley 2023-02-01
Series:Immunity, Inflammation and Disease
Subjects:
biologic therapy
hepatitis B virus
reactivation
rheumatoid arthritis
Online Access:https://doi.org/10.1002/iid3.780

Internet

https://doi.org/10.1002/iid3.780

Similar Items